Various systemic therapies for psoriasis either reduced, slightly increased or had no effect on risk for major adverse ...

Zoryve (roflumilast) topical foam, 0.3% Phosphodiesterase type 4 inhibitor Treatment of plaque psoriasis of the scalp and body in adult and pediatric patients aged 12 years and older. Zoryve Foam 0.3% ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Abdominal obesity is a greater risk factor for psoriasis than total body fat, according to an analysis of imaging data, ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

Genetics do not alter the connection between //abdominal fat and psoriasis Excess fat stored around the abdomen appears to ...

Although manuka honey may not treat the underlying cause of psoriasis, research suggests it may help reduce skin inflammation ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

VedicDerm launches a steroid-free Ayurvedic psoriasis cream, scientifically proven to reduce inflammatory markers by up to 99 ...

People with psoriasis persist with IL23p19 inhibitors up to an estimated ... based on the patient's history of having PsA ...

NutritionistLearn all about psoriasis, a chronic inflammatory disease, including common symptoms, treatments, plus which diet ...